[Form 4] Air Products & Chemicals, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Jessica Graziano, a director of Air Products & Chemicals, Inc. (APD), reported a Section 16 transaction dated 09/30/2025. The filing shows acquisition of 156.6796 phantom deferred stock units under the company’s Deferred Compensation Program for Directors, granted under the Long-Term Incentive Plan. The units are payable in shares of common stock equal to the number of units, at a time elected by the reporting person, typically after board service ends, and may be paid in a lump sum or up to ten installments.
The filing lists a reference price of $270.48 and reports 2,183.889 shares beneficially owned following the transaction. The form is signed by an attorney-in-fact on behalf of the reporting person.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director received deferred phantom stock units that convert to common shares after service, modestly increasing beneficial ownership.
The report documents a grant of 156.6796 phantom deferred stock units to Director Jessica Graziano under the issuer’s director deferred compensation plan. These units convert to an equal number of common shares when paid, typically after board service, with payout timing and installment options elected in advance. The filing lists a reference price of $270.48 and shows total beneficial ownership of 2,183.889 shares following the reported transaction. This appears to be a routine director compensation event rather than a market-moving transaction.
TL;DR: This is a standard deferred-compensation grant to a director with customary payout terms tied to post-service elections.
The description explicitly identifies the award as Phantom deferred stock units under the Air Products Stock Account of the Deferred Compensation Program for Directors, governed by the Long-Term Incentive Plan. The units convert one-for-one to common stock at the election of the reporting person, with payment timing options including lump sum or up to ten installments. The filing is executed by an attorney-in-fact and does not indicate any changes to director status or unusual vesting conditions.